Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.
Type:
Grant
Filed:
December 21, 2011
Date of Patent:
July 2, 2013
Assignee:
Pisgah Laboratories, Inc.
Inventors:
Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.
Type:
Grant
Filed:
December 29, 2011
Date of Patent:
February 5, 2013
Assignee:
Pisgah Laboratories, Inc.
Inventors:
Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.
Type:
Grant
Filed:
December 28, 2011
Date of Patent:
December 25, 2012
Assignee:
Pisgah Laboratories, Inc.
Inventors:
Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.
Type:
Grant
Filed:
January 18, 2011
Date of Patent:
December 11, 2012
Assignee:
Pisgah Laboratories, Inc.
Inventors:
Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.
Type:
Grant
Filed:
April 14, 2009
Date of Patent:
July 3, 2012
Assignee:
Pisgah Laboratories, Inc.
Inventors:
Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
Abstract: An amorphous form of imipramine pamoate, morphologically pure forms, and mixtures of amorphous and morphologically pure imipramine pamoate characterized by differential scanning calorimetry, fourier transform infrared, and powder x-ray diffraction, and pharmaceutical compositions formed therefrom.
Type:
Grant
Filed:
August 23, 2007
Date of Patent:
October 18, 2011
Assignee:
Pisgah Laboratories, Inc.
Inventors:
Vicki Haynes Audia, David William Bristol, Joseph Pike Mitchener, Jr., Clifford Riley King
Abstract: A pharmaceutical composition comprising the salt of a thyroid hormone selected from the group consisting of levothyroxine and liothyronine and an organic acid comprising at least one aromatic ring having at least one hydroxyl moiety and at least one carboxylic acid moiety in an ortho relationship.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
December 28, 2010
Assignee:
Pisgah Laboratories, Inc.
Inventors:
David William Bristol, Clifford Riley King, Vicki Haynes Audia